Small
Frazier Life Sciences Boosts Evergreen Fund with $630M for Small and Mid-Cap Biotechs
Frazier Life Sciences, Evergreen Fund, Small and Mid-Cap Biotechs, Healthcare Investment, Biotechnology Funding
Promising Phase 2 Results for Ifinatamab Deruxtecan in Small Cell Lung Cancer
Ifinatamab Deruxtecan, Small Cell Lung Cancer, Phase 2 Trial, ADC Technology, Daiichi Sankyo, Merck